Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial

Published 2018 View Full Article

Authors

Keywords

Journal

LANCET ONCOLOGY

Volume 20, Issue 1, Pages 43-56

Publisher

Elsevier BV

Online

2018-12-04

DOI

10.1016/s1470-2045(18)30788-5

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Reprint

Contact the author

Find the ideal target journal for your manuscript

Explore over 38,000 international journals covering a vast array of academic fields.

Ask a Question. Answer a Question.

Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.

Get Started